Drug Profile
Research programme: allogeneic umbilical cord-derived mesenchymal stem cell therapy - AbelZeta Pharma
Alternative Names: huMPC; Umbilical cord-derived mesenchymal progenitor cell therapy - AbelZeta PharmaLatest Information Update: 27 Nov 2023
Price :
$50
*
At a glance
- Originator Cellular Biomedicine Group
- Developer AbelZeta Pharma
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Glaucoma; Systemic lupus erythematosus